ClinicalTrials.gg
CompletedNCT02171533Updated Jun 24, 2014

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

A Phase 1 interventional study of dabigatran and Verapamil in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To investigate whether and to what extent the P-glycoprotein inhibitor (P-gp) verapamil affects the pharmacokinetic parameters of dabigatran with verapamil given at different dosages, in different formulations (immediate release (IR) and extended release (ER)), and in different intervals in relation to the dabigatran dose.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), clinical laboratory tests
  2. Age ≥18 and ≤55 years
  3. (BMI) ≥18.5 and BMI ≤29.9 kg/m2
  4. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation

Exclusion criteria

Exclusion criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Relevant surgery of gastrointestinal tract
  3. History of any bleeding disorder or acute blood coagulation defect
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  8. Pulse rate below 50 bpm and or systolic blood pressure \<90 mm Hg at screening. : PR >170 ms (Part 1), AV block ≥1st degree (Part 2) at screening
  9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, cumarin etc.
  10. Participation in another trial with an drug within two months prior to administration or during the trial
  11. Smoker (more than 15 cigarettes or 3 cigars or 3 pipes per day)
  12. Alcohol abuse (more than 60 g/day for men and more than 40 g/day for women)
  13. Drug abuse
  14. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  15. Excessive physical activities (within one week prior to administration or during the trial)
  16. Any laboratory value outside the reference range that is of clinical relevance
  17. Planned surgeries within four weeks following the end-of study examination
  18. The subject is not able to understand and comply with protocol requirements, instructions, protocol-stated restrictions and dietary regimen of study centre

    For male subjects:

  19. Male subjects who do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the post study medical. Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two month)

    For female subjects:

  20. Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
  21. No adequate contraception during the study and until 1 month of study completion, i.e. implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females, who have not a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide)
  22. Lactation period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Fixed sequence

    Treatments will be given in a fixed sequence

    Drug: dabigatran · Drug: Verapamil

  • Experimental
    Crossover

    Treatments will be given in randomized sequences

    Drug: dabigatran · Drug: Verapamil · Drug: Verapamil ER

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-infinity (area under the concentration-time curve of total dabigatran over the time interval from 0 extrapolated to infinity)

    Time frame: up to 107 hours

  2. Cmax (maximum measured concentration of total dabigatran)

    Time frame: up to 107 hours

Secondary outcomes

  1. AUC0-infinity (area under the concentration-time curve of free dabigatran over the time interval from 0 extrapolated to infinity)

    Time frame: up to 107 hours

  2. Cmax (maximum measured concentration of free dabigatran)

    Time frame: up to 107 hours

  3. AUC0-infinity (area under the concentration-time curve of verapamil over the time interval from 0 extrapolated to infinity)

    Time frame: up to 107 hours

  4. Cmax (maximum measured concentration of verapamil)

    Time frame: up to 107 hours

  5. AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: up to 107 hours

  6. AUC0-24 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after the administration)

    Time frame: up to 107 hours

  7. tmax (time from dosing to the maximum concentration of the analyte in plasma)

    Time frame: up to 107 hours

  8. λz (terminal rate constant in plasma)

    Time frame: up to 107 hours

  9. t1/2 (terminal half-life of the analyte in plasma)

    Time frame: up to 107 hours

  10. MRTpo (mean residence time of the analyte in the body after oral administration)

    Time frame: up to 107 hours

  11. CL/F (apparent clearance of the analyte in the plasma after extravascular administration)

    Time frame: up to 107 hours

  12. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Time frame: up to 107 hours

  13. AUCτ,ss (area under the concentration-time curve of verapamil within the uniform dosing interval τ)

    Time frame: up to 107 hours

  14. AUC0-tz,ss (area under the concentration-time curve of verapamil from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)

    Time frame: up to 107 hours

  15. Cmax,ss (maximum concentration of verapamil at steady state)

    Time frame: up to 107 hours

  16. tz,ss (time of last measureable concentration of verapamil within the dosing interval τ at steady state)

    Time frame: up to 107 hours

  17. tmax,ss (time from last dosing to the maximum concentration of verapamil at steady state on day 4)

    Time frame: up to 107 hours

  18. CL/F,ss (apparent clearance of verapamil at steady state after extravascular multiple dose administration)

    Time frame: up to 107 hours

  19. Cmin,ss (minimum measured concentration of verapamil at steady state over a uniform dosing interval τ)

    Time frame: up to 107 hours

  20. tmin,ss (time from last dosing to the minimum concentration of verapamil at steady state over a uniform dosing interval τ)

    Time frame: up to 107 hours

  21. Cpre,ss (predose concentration of verapamil at steady state immediately before administration of the next dose)

    Time frame: up to 107 hours

  22. Cavg (Average concentration of verapamil at steady state)

    Time frame: up to 107 hours

  23. MRTpo,ss (mean residence time of verapamil in the body at steady state after oral administration)

    Time frame: up to 107 hours

  24. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)

    Time frame: up to 107 hours

  25. Ae0-24 (amount of dabigatran that is eliminated in urine from the time interval 0-24h)

    Time frame: up to 107 hours

  26. fe0-24 (fraction of administered drug excreted unchanged in urine from time point 0- 24h)

    Time frame: up to 107 hours

  27. CLR0-24 (renal clearance of dabigatran from the time point 0 until the time point 24h )

    Time frame: up to 107 hours

  28. AUEC0-24 (area under the effect curve)

    for ecarin clotting time and thrombin time

    Time frame: up to 107 hours

  29. ERmax (maximum effect ratio)

    for ecarin clotting time and thrombin time

    Time frame: up to 107 hours

  30. Occurence of Adverse Events

    Time frame: within 5 days after last drug administration

  31. Assessment of Tolerability by investigator

    Time frame: within 5 days after last drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Jun 2008
Primary completionActual
Aug 2008
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171533
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Jun 2008
Primary completion
Aug 2008
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Verapamil

Start the discussion